Tracers / [11C]LY2795050

[11C]LY2795050

Also written as [11C]LY2795050; [C-11]LY2795050
Radionuclide
C-11 t½ 20.36 min
Modality
PET
Production route
Stage
Syntheses indexed
2

What it is

Compound class
benzamide
Target / mechanism
KOR antagonist PMID 40857482
Clinical application
Theranostic pair

Regulatory status

FDA
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
TRACERlab FX (model not stated)
GE HealthCare
HPLC8.4 ± 3.2%
yes
99.5 ± 0.7%17-I40857482
2025 Asian J Org Chem
The methodology uses GE TRACERLab FX automated radiochemistry synthesis modules — RCY of 8.4 ± 3.2% (25 ± 9 mCi (942 ± 352 MBq) at end-of-syntheses, corresponding to 1.0 ± 0.41% non-decay-corrected RCY based upon ~92.5 GBq (~2.5 Ci) of starting [11C]CO, 62 min synthesis, n = 3)
near quantitative37513867
2023 Pharmaceuticals (Basel)

Need this precursor?We can point you to suppliers for [11C]LY2795050, or handle the enquiry for you.

Get in touch

Quality control Preliminary — inferred from compound class

Ph. Eur. monograph
USP monograph
AppearancepHRCP HPLCRCP TLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrity
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [11C]LY2795050.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with C-11.